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A B S T R A C T
We present a rare case of cardiac malignant ﬁbrous histiocytoma (MFH; undifferentiated pleomorphic
sarcoma); to date, fewer than 100 cases of cardiac MFH have been reported. In this case, transthoracic
echocardiography revealed cardiac tumors in the left atrium (LA) of a 53-year-old woman with a 3-
month history of worsening dyspnea; the largest tumor was found to protrude through the mitral valve
in diastole, causing stenosis. Three of the four tumors were resected during emergency surgery;
however, the residual tumor extension into the left pulmonary vein could not be removed. Histological
ﬁndings of the resected tumors, such as organized thrombus and myxomatous tissue changes, indicated
that the tumors were benign. After 3 months, the patient underwent total resection for a small mass that
developed on her right abdominal wall, which was revealed histologically to be MFH; additionally, the
residual mass in the LA had enlarged progressively. After undergoing radiation therapy without further
surgery, she died of cerebral bleeding 6 months after cardiac surgery. Postmortem examination revealed
that the tumor in the LA was an MFH. Thus, cardiac MFH should be considered as a differential diagnosis
for tumors on the posterior wall of the LA.
<Learning objective: Primary cardiac malignant ﬁbrous histiocytoma (MFH), which is easily mistaken
for atrial myxoma, is a rare type of cardiac sarcoma. MFH occurs most commonly on the posterior wall of
the left atrium (LA), and total resection is currently the only effective therapy; however, the prognosis is
poor. Therefore, a high level of suspicion is required to facilitate early diagnosis. Cardiac MFH should be
considered as a differential diagnosis for tumors on the posterior wall of the LA.>
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Malignant ﬁbrous histiocytoma (MFH; undifferentiated pleo-
morphic sarcoma) was initially described by O’Brien and Stout in
1964 [1] and is currently regarded as the most common type of
soft-tissue sarcoma in adults. MFH arises commonly in the
extremities and trunk, and the likelihood of local recurrence and* Corresponding author at: Division of Cardiology, Tane General Hospital,
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2001, Okamoto et al. reported 1 case of cardiac MFH and reviewed
the 46 previously described cases [2]. Total tumor resection is the
only effective therapy for this presentation of MFH, and the
prognosis is poor. We present herein a case of acute heart failure
consequent to cardiac MFH and discuss the features of this tumor.
Case report
A 53-year-old woman was hospitalized because of increasing
dyspnea; she additionally reported a continuous dry cough of
3 months’ duration, with a history of cerebral hemorrhage 10 years
earlier. On admission, her pulse rate was 100 regular beats/min reserved.
Fig. 1.
(A) A chest radiograph showing pleural effusion and pulmonary edema. (B) A transthoracic echocardiogram showing a movable mass (28 mm  26 mm) attached
to the posterior wall (arrow). (C) The surgical view showing the movable mass during its excision from the wall of the left atrium (arrow). (D) Gross examination
of the 3 resected tumors.
Fig. 2.
(A) A cardiac magnetic resonance imaging scan showing a residual mass on the wall of the left atrium (LA) (arrow). (B) A transesophageal echocardiogram also
showing the mass in the LA (arrow). (C) Gross cut surface of the subcutaneous abdominal tumor. (D) A photomicrograph of the abdominal tumor (hematoxylin–
eosin staining), showing the sarcomatous pattern of immature spindle cells. (E) An 18F-ﬂuorodeoxyglucose-positron emission tomography/computed
tomography scan showing the mass in the LA (arrow), but no additional metastases are observed.
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tion ﬁndings and peripheral edema were not observed. Oxygen
saturation as measured by pulse oximetry was 94% in room air.
Chest radiography revealed a ground glass-like shadow in both
lower lung lobes. Electrocardiography indicated mild left atrial
overload and mild QT elongation. Laboratory studies disclosed the
following values: hemoglobin level, 13.6 g/dL; white blood cell
count, 9600/mm3 with a left shift; C-reactive protein level,
2.39 mg/dL; and brain natriuretic peptide, 73 pg/mL (normal:
<18 pg/mL). Her other common laboratory results indicated
no particular abnormalities. She was hospitalized with a diagnosis
of interstitial pneumonia, and antibiotic therapy was initiated.
On the third hospital day, she experienced dyspnea while at rest.
Chest radiography revealed pleural effusion and pulmonary edema
(Fig. 1A). Transthoracic echocardiography revealed 2 cardiac tumors
in the left atrium (LA): one tumor was a movable mass attached to
the posterior wall that protruded through the mitral valve in diastole
to cause mitral stenosis (Fig. 1B) and the other was strap-shaped and
mobile within the LA. A provisional diagnosis of LA myxoma was
made. The patient underwent emergency surgical resection (Fig. 1C),
during which 4 tumors were observed and 3 were resected (Fig. 1D);
however, one tumor had extended into the left pulmonary vein and
could not be removed from the wall of the LA. Histological
examination of the tumors revealed organized thrombus and
myxomatous tissue with no malignant ﬁndings. Postoperative
transesophageal echocardiography and cardiac magnetic resonance
imaging (MRI) revealed a residual 20-mm  30-mm tumor on theFig. 3.
(A) A contrast non-gated computerized tomography scan of the chest sho
echocardiogram showing a movable mass that had extended into the mitral
pulmonary vein (*). (D) A photomicrograph of the cardiac tumor (hematoxyposterior wall of the LA that had obstructed the left pulmonary vein
(Fig. 2A and B). Thus, these ﬁndings suggested a sarcoma.
The patient noted a small mass on her right abdominal wall at
3 months post-surgery; the mass rapidly increased to 6 cm  7 cm
in size within a 2-month period. This tumor was totally resected
(Fig. 2C). Histological evaluation of the abdominal wall tumor
revealed moderate cellular proliferation of oval- to spindle-shaped
cells with highly nuclear atypia and intermittent mitosis (Fig. 2D).
These cells were immunohistochemically positive for vimentin
and negative for epithelial membrane antigen, cytokeratin
(CAM5.2), a-smooth muscle actin, S-100, and CD34. The MIB-1
cell proliferation labeling index was 45%. The tumor diagnosis was
conﬁrmed as an MFH. 18F-ﬂuorodeoxyglucose-positron emission
tomography/computed tomography detected the mass in the LA
but did not ﬁnd evidence of metastasis (Fig. 2E).
Gradually, the residual mass in the LA increased in size (Fig. 3A),
and the unﬁxed portion extended into the mitral annulus (Fig. 3B).
The patient complained of dizziness; cranial MRI revealed 3 new
small infarctions, and we initiated warfarin therapy. We consulted
with cancer specialists at 2 hospitals and both judged chemother-
apy to not be indicated. Despite our recommendation for
additional cardiac surgery, the patient selected radiation therapy.
After receiving a total radiation therapy dose of 20 Gy, she was
admitted to our hospital with cerebral bleeding and a prothrom-
bin-international normalized ratio and a D-dimer value of 1.68 and
0.9 mg/mL (normal 0.0–1.0 mg/mL), respectively. She died of
cerebral bleeding 7 days later at 6 months after the cardiacwing a mass of increasing size in the left atrium (arrow). (B) A transthoracic
 annulus (arrow). (C) A cardiac tumor at autopsy (arrow) with invasion into the
lin–eosin), demonstrating malignant ﬁbrous histiocytoma.
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recurrent tumor into the left pulmonary vein (Fig. 3C). The
pathological diagnosis of the cardiac tumor was MFH, the same as
the abdominal tumor (Fig. 3D). One-third of the cardiac tumor had
become necrotic, and the MIB-1 labeling index was 3%. We
observed a micrometastasis of the right adrenal gland as well as
infarctions in the spleen and right kidney. A brain examination was
not permitted by patient’s next-of-kin.
Discussion
Primary cardiac tumors are rare, with a reported incidence of
only 0.02% as determined by autopsy [3]. The majority of these
tumors are benign myxomas, although a quarter of cases are
malignant, most of which are sarcomas. Angiosarcoma is the most
common type of cardiac sarcoma [4]. Although MFH is considered
the most common type of soft-tissue sarcoma in adults, primary
cardiac MFH is rare. Shah et al. reported the ﬁrst case of cardiac
MFH in 1978 [5]. Subsequently, Okamoto et al. reported a case of
MFH that arose from the LA and reviewed an additional
46 previously reported cases [2]. An analysis of those 47 cases
revealed that 29 patients (62%) were women and 18 were men
(38%), with a mean overall age of 47.1 years. Cardiac MFH was
found to occur most frequently in the LA and to usually attach to
the posterior wall. The organs most often affected by metastasis
include the brain, lung, bone, and adrenal glands.
The clinical characteristics of the present patient were similar
to those in previous reports with respect to age, sex, tumor
location, and metastasis. Because our ﬁrst priority was emergency
surgery, we were unable to perform a sufﬁcient preoperative
examination and failed to completely resect the tumor, leading to a
local recurrence and remote metastasis. The rapid growth of the
subcutaneous metastatic tumor in this case is noteworthy. As the
subcutaneous tissue was originally a breakthrough area for the
MFH, the tumor environment might have facilitated this growth.
Furthermore, most tissues removed during the cardiac operation
were organized clots, indicating that MFH might readily clot and
embolize. As we conﬁrmed brain infarction by MRI and infarction
of the right kidney and the spleen by autopsy, the existence of
cerebral embolism is possible. Although a brain examination was
not permitted by the patient’s next-of-kin, cerebral bleeding might
have been partly related to MFH.
Multimodal therapy (e.g. surgery, radiation therapy, and
chemotherapy) is the standard treatment protocol for treatmentof MFH in the extremities and trunk [6]. In contrast, the only
currently effective therapy for cardiac MFH is total resection
[7,8]. However, a recent article reported an association between
multimodality therapy for the treatment of primary cardiac
sarcoma and improved survival [9]. Although multimodality
therapy for cardiac MFH remains controversial [10], we provided
radiation therapy at a total dose of 20 Gy to our patient after
receiving informed consent. However, the effectiveness of this
therapy was unclear. Irradiation might have exerted some effect on
the tumor, as moderate necrosis and a decreased MIB-1 index were
observed during the autopsy.
We experienced a rare case of cardiac MFH on the posterior wall
of the LA, the most common presenting location. Total tumor
resection remains the only effective treatment for such cases.
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